A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/26/2002	US20020198232 4-substituted quinoline derivatives
12/26/2002	US20020198231 Compositions and methods for the treatment of Parkinson's disease
12/26/2002	US20020198229 Polymorphic form of clopidogrel hydrogen sulphate
12/26/2002	US20020198228 Composition and method for the treatment of respiratory desease
12/26/2002	US20020198227 Administering to a obese or diabetic patient a low dose of naltrexone for reducing carbohydrate craving
12/26/2002	US20020198226 Administration of an opioid analgesic agent(such as morphine, codeine, methadone and fentanyl) and a compound that binds to the SS1 or SS2 subunit of a sodium channel , such as tetrodotoxin and saxitonxin and derivatives
12/26/2002	US20020198225 Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines
12/26/2002	US20020198224 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
12/26/2002	US20020198219 2-pyridinamine compositions and related methods
12/26/2002	US20020198216 Novel farnesyl protein transferase inhibitors as antitumor agents
12/26/2002	US20020198214 Such as (3-(4-(4-fluoro-benzyl)-piperidine-1-carbonyl)-4-methoxy-phenyl)-oxo-acetic acid methyl ester for proinflammation response in multiple sclerosis, inflammatory bowel disease, osteoarthritis, and other arthritic conditions
12/26/2002	US20020198213 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
12/26/2002	US20020198212 Optically active compounds
12/26/2002	US20020198210 Alpha-2-adrenergic agonist/fatty acid compositions
12/26/2002	US20020198208 Medicinal preparation and process for manufacturing thereof
12/26/2002	US20020198206 Such as 1-Cyclohexyl-4-(4-fluorophenyl)-5-((2-phenylamino)pyrimidin-4-yl)imidazole; for use as cytokine inhibitors
12/26/2002	US20020198203 Administering (2R)-2-(4-(9-Bromo-2,3-dimethyl-naptho(2,3-b) thiophen-4-yl)-2,6-dimethyl-phenoxy)-3-phenyl-propionic acid to treat metabolic disorders mediated by insulin resistance or hyperglycemia
12/26/2002	US20020198202 Combination of a PTPase inhibitor and an antilipemic agent
12/26/2002	US20020198201 Administering (R)-2-(2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho(2,3-b)thiophen-4-yl) -phenoxy)-3-phenyl-propionic acid to lower free fatty acid blood levels in diabetic mammals
12/26/2002	US20020198200 Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators
12/26/2002	US20020198199 Such as 2-(2-(N-((4-aminoiminomethylphenyl)methyl)-3-(3-aminophenyl)-6-(N,N -dimethylhydrazino)-1-oxypyridinyl))acetami de which inhibit serine proteases for preventing and treating thrombotis
12/26/2002	US20020198198 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
12/26/2002	US20020198197 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders
12/26/2002	US20020198196 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
12/26/2002	US20020198195 New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa
12/26/2002	US20020198194 Neuropeptide Y (NPY) antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, or obesity
12/26/2002	US20020198193 Novel 5-thio-B-D-xylopryanoside derivatives, preparation, method, pharmaceutical compositions containing them and their therapeutic use
12/26/2002	US20020198192 A therapeutic formulation comprising a topically acceptable non-solid vehicle and carbamazepine for treating psoriasis skin disorder; gels, creams, ointments, lotions, liquids, and suspensions
12/26/2002	US20020198191 Cyclohexylphenyl vasopressin agonists
12/26/2002	US20020198190 Tetracyclic 1,2,3,4,5,6- hexahydroazepino-(4,5-b)indole derivatives having a ring connecting position 6 (N-6) and position 7 (C-7); treating or preventing a disease or disorder of the central nervous system in a mammal
12/26/2002	US20020198189 Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans
12/26/2002	US20020198187 Method of treating sexual disturbances
12/26/2002	US20020198184 Matrix metalloproteinase inhibitor is useful as an anticancer agent, angiogenesis inhibitor, a tumor cell infiltration inhibitor or a tumor metastasis inhibitor; inflammatory diseases, osteoarthritis, rheumatoid arthritis
12/26/2002	US20020198183 Treatment of cancer with thymidine in combination with temozolamide
12/26/2002	US20020198182 Malignant tumor metastasis inhibitors
12/26/2002	US20020198180 Penicillanic acid derivative compounds and methods of making
12/26/2002	US20020198179 An estrogen or prodrug micture for reducing or eliminating the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer, inhibiting the development of osteoporosis
12/26/2002	US20020198178 Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS
12/26/2002	US20020198177 Coenzyme Q and EPA
12/26/2002	US20020198176 Treatment of psoriasis with matrix metalloproteinase inhibitors
12/26/2002	US20020198175 Administering a selected modified or unmodified resistant starch or mixtures thereof; amylose starch obtained from maize, barley, and legumes, bananas, potatoes, rice or wheat starch
12/26/2002	US20020198174 Disinfecting and solubilizing steroid compositions
12/26/2002	US20020198173 Viricides for treating HIV and hepatitis virus
12/26/2002	US20020198171 Administering to a hepatitis B infection patient an effective treatment amount of a 2'fluoro- beta -D-nucleoside or salts(containing purine or pyrimidine base)
12/26/2002	US20020198170 Formulations of adenosine a1 agonists
12/26/2002	US20020198169 L-ergothioneine, milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
12/26/2002	US20020198165 Nucleic acids for the prevention and treatment of gastric ulcers
12/26/2002	US20020198164 A toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence
12/26/2002	US20020198161 Sulphur-containing antioxidant is selected from the group consisting of N- acetylcysteine, 2,3-dimercaptopropanol, L-2-oxo-4-thiazolidinecarboxylate and lipoic acid, useful for cancer treatment
12/26/2002	US20020198160 Compositions and methods for enhancing the bioavailability of pharmaceutical agents
12/26/2002	US20020198159 Use of stilbene derivatives substituted in position 3 as deodorant active agents in cosmetic compositions
12/26/2002	US20020198158 A cyclic ether conatining atleast 3 carbon atoms; sugars; useful as antidiabetic agents
12/26/2002	US20020198156 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor
12/26/2002	US20020198155 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
12/26/2002	US20020198153 Administering to an individual for tumor treatment a chemotherapeutically effective amount of antitumor agent carboplatin, and erythropoietin a hematocrit elevator which is administered befor or concurrently with antitumor agent
12/26/2002	US20020198152 Administering to an obese patient or one at risk of becoming obese a therapeutic compound that attenuates the binding of agouti-related protein to melanocortin receptors, free of binding of alpha-melanocyte stimulating hormone to receptor
12/26/2002	US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002	US20020198141 Molecular conjugates for use in treatment of cancer
12/26/2002	US20020198138 Combination therapy for the treatment of inflammatory and respiratory diseases
12/26/2002	US20020198137 Antineoplastic combinations
12/26/2002	US20020198136 Treating vaginismus, dyspareunia, interstitial cystitis, vulvodynia, vulvar vestibulitis, nonspecific urethritis, female sexual arousal orgasmic disorders or increasing vaginal lubrication, etc.
12/26/2002	US20020197737 Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
12/26/2002	US20020197712 Polypeptide for use as tools in analyzing enzymatic gene expression
12/26/2002	US20020197692 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
12/26/2002	US20020197683 Metabolic controlled fermentation process for carbamoyl tobramycin production
12/26/2002	US20020197675 Glial nerovus system modulator for use in the treatment of nervous system disorders and spine damage
12/26/2002	US20020197609 Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
12/26/2002	US20020197602 Nucleic acid sequences and proteins associated with aging
12/26/2002	US20020197599 Novel adjuvants and copolymer compositions
12/26/2002	US20020197381 Caffeine complexes with enhanced taste, process for their preparation and their use
12/26/2002	US20020197340 Chromium picolinate compositions and uses threof
12/26/2002	US20020197337 Hypericum Perforatum L. Oleoresin, Procedure for Obtaining it and Uses of it
12/26/2002	US20020197334 Pharmaceutical composition for the treatment of diabetes mellitus
12/26/2002	US20020197331 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
12/26/2002	US20020197327 Taste masked pharmaceutical compositions
12/26/2002	US20020197325 Microparticles
12/26/2002	US20020197320 Composition and method for rectal delivery of a lincosamide antibiotic drug
12/26/2002	US20020197318 Compositions
12/26/2002	US20020197312 Dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
12/26/2002	US20020197311 Pharmaceutical preprations containing pyrogenic silicon dioxide
12/26/2002	US20020197310 Analgesics; solid dosage form
12/26/2002	US20020197309 Administering antidiabetic agent, glipizide
12/26/2002	US20020197308 Rapidly soluble drug composition
12/26/2002	US20020197307 Containing venlafaxine hydrochloride; side effect reduction
12/26/2002	US20020197306 Cationic lipid compositions targeting angiogenic endothelial cells
12/26/2002	US20020197304 Compositions for the treatment and prevention of cancer
12/26/2002	US20020197301 Animal body fat control
12/26/2002	US20020197300 Drug delivery system for anti-glaucomatous medication
12/26/2002	US20020197298 Interior core in well containing active materials; aperture to exterior
12/26/2002	US20020197291 Mixture of urea, hydrophilic film forming compound and water
12/26/2002	US20020197288 Topical applying; mixture of fibers and ubiquinone
12/26/2002	US20020197286 Method for preventing and treating skin aging
12/26/2002	US20020197284 Transdermal and topical administration of local anesthetic agents using basic enhancers
12/26/2002	US20020197283 Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
12/26/2002	US20020197277 Cell culture system for synthesis of infectious hepatitis C virus
12/26/2002	US20020197275 Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals
12/26/2002	US20020197274 Lithospermic acid-containing composition
12/26/2002	US20020197255 Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
12/26/2002	US20020197245 Antitumour compositions containing taxane derivatives
12/26/2002	US20020197244 Compositions and methods for regulating phagocytosis and ICAM-1 expression

1 ... 5610 5611 5612 5613 5614 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 ... 7860